肥胖与慢性肾脏病:肾易损性与风险分层的CKM框架
本文综述提出心血管-肾脏-代谢(CKM)综合征框架解释肥胖相关CKD的异质性。肥胖通过血流动力学、代谢毒性、脂肪组织等多因素导致肾单位负荷增加和肾小球高压,进而出现白蛋白尿和肾功能进展。作者提出四个CKM相关肾易损域,用于识别高危个体、早期筛查和预防。
要点
- 肥胖仅部分个体发生CKD,需CKM框架识别肾易损性。
- 肾小球高压和高滤过是肥胖肾损伤的共同通路。
- 四个CKM肾易损域有助于风险分层和早期筛查。
核心结论
- CKM综合征框架可解释肥胖相关CKD的异质性并指导风险分层。
研究设计与样本
- 综述,未报告系统检索范围与样本量。
主要发现
- 肥胖通过血流动力学应激、代谢毒性/胰岛素抵抗、内脏和异位脂肪、炎症、氧化应激、脂肪因子失衡及肾单位储备减少等促进肾易损。
- 上述因素汇聚于单肾单位负荷增加、适应性肾小球高滤过和肾小球内高压,继而足细胞应激、白蛋白尿和进行性肾损伤。
关键数值与推荐
- 提出四个重叠的CKM相关肾易损域,用于识别CKD高风险个体。
临床怎么用
- 对肥胖患者应基于CKM框架评估肾易损性,支持早期筛查和纵向监测。
- 预防策略应针对CKM相关肾易损域进行风险分层。
局限性
- 为概念性综述,未提供具体阈值、剂量或干预试验数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Obesity is an important risk factor for chronic kidney disease (CKD), yet only a subset of individuals with obesity develops albuminuria, declining estimated glomerular filtration rate (eGFR), and progressive kidney disease. This variability indicates that excess body weight alone is insufficient to explain obesity-induced kidney injury. In this review, we propose that cardio-kidney-metabolic (CKM) syndrome provides a useful framework to understand this heterogeneity. We discuss major pathophysiological contributors to kidney vulnerability in obesity, including haemodynamic stress, metabolic toxicity/insulin resistance, visceral and ectopic fat, inflammation, oxidative stress, adipokine imbalance, and reduced nephron reserve. Several of these contributors converge on a common intrarenal pathway characterized by increased single-nephron workload, maladaptive glomerular hyperfiltration and intraglomerular hypertension, followed by podocyte stress, albuminuria, and progressive kidney injury. On this basis, we propose a conceptual framework comprising four overlapping CKM-related kidney vulnerability domains, which may help identify individuals at increased CKD risk, support earlier screening and longitudinal monitoring, and inform preventive strategies.
引用
- Bozic M, Theodorakopoulou M, Bevc S, et al. Obesity and chronic kidney disease: a cardio-kidney-metabolic framework for renal vulnerability and risk stratification. Nephrol Dial Transplant. 2026. PMID: 42799669. doi:10.1093/ndt/gfag221
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。